Aspen Neuroscience, Inc S-1, filed Oct 9, 2026

Aspen Neuroscience, Inc. (ASPE)

Aspen Neuroscience, Inc. is pursuing an initial public offering of common stock and plans to list it on Nasdaq Global Select Market under “ASPE.” Its lead candidate, sasineprocel, is being evaluated for Parkinson’s disease, with 15 patients dosed. AI summary